Platelet-mimicking particles are bioengineered constructs that functionally replicate the size, shape, and mechanical properties of natural platelets, which assist various hemostatic mechanisms. Also known as synthetic platelets, these biosynthetic particles are recent advancements in the field of drug delivery where they enable targeted interactions that enhance hemostasis, minimize bleeding risks, and support localized therapies. Their applications extend to thrombosis, inflammation, and cancer treatment, as well as significant potential in trauma care, cardiovascular therapies, and immunotherapy. They also address limitations of natural platelet transfusions, such as limited availability, short shelf life, and safety concerns.

The design and manufacture of platelet-mimicking particles is diverse across current methods and involves precise biomaterial selection, nanoparticle engineering, surface functionalization, and scalable production techniques. Many of these designs include decorating microspheres with specialized antibodies and peptides that can bind to circulating tumor cells and facilitate their removal or altering their shape upon thrombin exposure to accelerate wound healing. Another approach engineers these platelets with a discoidal shape and flexible polymer composition to mimic platelet deformation under shear forces. While these varied approaches aim to optimize surface interactions and hemostatic performance for multiple therapeutic applications, current research on synthetic platelets is primarily in the preclinical stage. The majority of synthetic platelet studies rely on animal models to assess their safety, efficacy, and hemostatic performance. In various experimental models, platelet-mimicking particles have demonstrated the ability to reduce bleeding and improve survival rates, which mirrors the fundamental functions of natural platelets. While these findings suggest promising therapeutic applications, further research is required to refine synthetic platelet designs that ensure long-term safety and facilitate clinical translation for human use.

Platelet-mimicking particles, an innovation of drug delivery since the mid-twentieth century, are designed to mimic the functionality of natural platelets, with ongoing research focusing on optimizing their biocompatibility, clot integration, and targeted delivery capabilities. Advances in nanotechnology and molecular engineering have enabled the development of platelet-mimicking drug delivery systems. Current research aims to replicate key platelet functions such as adhesion, aggregation, and clotting to enhance hemostatic responses and targeted therapies. Primary synthetic platelet preparations involve nanoscale polymeric architectures, peptides, or extracellular vesicles to improve biocompatibility and therapeutic efficacy. Current iterations of synthetic platelets - hydrogel-based nanoparticles that mimic the size, mechanics, and shape of natural platelets - have demonstrated efficacy in promoting clotting and wound healing in preclinical studies involving rodents and pigs.

Originally designed to improve patient outcomes related to hemostasis, synthetic platelets are now being explored in other therapeutic areas including immune modulation and anticancer treatment. For example, a recent platelet design engineered for anticancer treatment can be freeze-dried and rehydrated when needed, offering a longer shelf life compared to natural platelets, which typically degrade rapidly when stored. This advancement could allow for assisted transport, making synthetic platelets a viable option in healthcare locations with limited resources, such as rural hospitals, ambulances, and battlefield settings.^{[citation needed]}

While preclinical results are encouraging, challenges remain in the large-scale clinical translation of synthetic platelets. Reproducibility, large-scale production, and safety issues must be addressed to gain regulatory approval and commercial viability. Researchers continue to refine synthetic platelet formulations by maximizing circulation time, stability, and biodegradability while minimizing undesirable immune responses. Additionally, studies have shown that synthetic platelets are excreted from the body within hours if they do not reach a wound site, which reduces the risk of unintended clotting in other parts of the body.

Native platelets play a vital role in hemostasis, the process of blood clotting and wound healing. Also known as thrombocytes, platelets are anucleate cell fragments derived from megakaryocytes in the bone marrow. Under healthy conditions, platelets circulate in an inactive state within the bloodstream and rapidly respond to vascular injury by initiating a complex cascade of coagulation events to prevent excessive blood loss. Native platelets are 2-3 micrometers in diameter and possess a highly specialized structure that enables their function in clot formation. Their cytoplasm contains dense granules and alpha granules, which store essential molecules such as adenosine diphosphate (ADP), serotonin, fibrinogen, and growth factors. These molecules are important for platelet activation, adhesion, and recruitment of additional platelets during vascular injury. The platelet membrane contains an abundance of glycoproteins, including integrins and receptors like glycoprotein Ib-IX-V and glycoprotein IIb/IIIa, which mediate interactions with the vascular endothelium and other platelets. A cytoskeleton composed of actin and tubulin allows platelets to change shape during activation, which extends filopodia to enhance adhesion and clot stability.

Platelets engage in the following three-step process to form a stable blood clot: adhesion, activation, and aggregation. When endothelial damage exposes the underlying extracellular matrix, adhesion begins in which von Willebrand factor binds to collagen, causing the recruitment of platelets through interactions with glycoprotein Ib receptors. This initial attachment allows platelets to stick to the damaged vessel wall. Upon adhesion, platelets undergo morphological changes and release bioactive molecules from their granules—signifying activation. Molecules like ADP and thromboxane A₂ increase the activation signal, which calls more circulating platelets to the injury site. Activation also leads to the expression of phosphatidylserine on the membrane surface. This acts as a catalytic platform for the coagulation cascade. Lastly, aggregation is performed as activated platelets express glycoprotein IIb/IIIa receptors, which bind fibrinogen and facilitate platelet-platelet interactions. This, in turn, leads to clot formation and stabilization and reinforces the platelet plug by converting fibrinogen into an insoluble fibrin mesh.

Platelets also have a key role in immune responses, inflammation, and tissue repair through their interactions with leukocytes and endothelial cells. To recruit immune cells to injury sites, activated platelets can release cytokines and chemokines such as platelet factor 4 (PF4) and transforming growth factor-beta (TGF-β). They also form platelet-leukocyte aggregates, which further enhance neutrophil and monocyte activation, in turn supporting pathogen clearance and inflammatory signaling. Platelets also promote angiogenesis and tissue regeneration to maintain overall vascular integrity by releasing growth factors like vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Their multifunctional role displays the challenge of innovating synthetic platelets capable of effectively replicating their physiological functions.